Samarth Parikh

Associate

Princeton

samarth.parikh@troutman.com

D 609.951.4160

OVERVIEW

Samarth is an associate in the firm's FDA Regulatory and Health Care and Life Sciences Transactional practices.

Before practicing law, Samarth served as an associate director at Janssen Pharmaceutical Companies of Johnson & Johnson, where he worked in various medical and regulatory roles. During his 10-year tenure at Janssen, he developed significant experience in areas such as adverse event reporting and analysis, preparing FDA regulatory responses and addressing regulatory inquiries, analyzing data from clinical trials and post-marketing studies, scientific and medical communications, product labeling, FDA inspections and audits, and other FDA regulatory matters. Samarth is also a licensed pharmacist.

TOP AREAS OF FOCUS

- FDA Regulatory + Risk Management Counseling
- Health Care Transactions

ALL AREAS OF FOCUS

- FDA Regulatory + Risk Management Counseling
- Health Care + Life Sciences
- Health Care Regulatory
- Health Care Transactions
- Life Sciences Transactions

PROFESSIONAL EXPERIENCE

- Associate director, Janssen Pharmaceutical Companies of Johnson & Johnson, 2019-2025
- Manager, Janssen Pharmaceutical Companies of Johnson & Johnson, 2018-2019
- Senior scientist, Janssen Pharmaceutical Companies of Johnson & Johnson, 2016-2018
- Fellow, Janssen Pharmaceutical Companies of Johnson & Johnson, 2015-2016

- Staff pharmacist, Rite Aid Pharmacy, 2016-2018

EDUCATION AND CERTIFICATIONS

EDUCATION

- Seton Hall University School of Law, J.D., *cum laude*, associate editor, *Seton Hall Law Review*; weekend representative, Health Law Forum
- Rutgers University, M.B.A.
- Philadelphia College of Pharmacy, Pharm.D., *summa cum laude*

BAR ADMISSIONS

- New Jersey

LANGUAGES

- Hindi
- Gujarati

PUBLICATIONS

- Co-author, "Outside FDA, Inside the Crosshairs: Cybersecurity Risks for General Wellness and Fitness Products," *Troutman Pepper Locke*, April 21, 2026.
- Co-author, "FDA Announces a Single Pivotal Trial as the New Default Standard for All Drug Approvals and Unveils a Plausible Mechanism Framework for Individualized Therapies," *Troutman Pepper Locke*, April 15, 2026.
- Co-author, "FDA's 2026 Guidance on General Wellness Devices: Policy for Low-Risk Devices," *Troutman Pepper Locke*, March 18, 2026.
- Co-author, "Wellness Trackers, 'Medical' Status, and Cybersecurity: How FDA, FTC, and State Laws Interlock," *Troutman Pepper Locke*, February 19, 2026.